An illustrative example is that of HER2 targeting in breast cancer, which results in significant improvement in life expectancy [159], whereas targeting the same receptor brings little benefit to treating other HER2+ malignancies, such as gastric cancer [158,160]. This evidence concerns the gene ERBB2 and breast carcinoma.